[go: up one dir, main page]

DK2738258T3 - ADAM6 mice - Google Patents

ADAM6 mice Download PDF

Info

Publication number
DK2738258T3
DK2738258T3 DK14154918.8T DK14154918T DK2738258T3 DK 2738258 T3 DK2738258 T3 DK 2738258T3 DK 14154918 T DK14154918 T DK 14154918T DK 2738258 T3 DK2738258 T3 DK 2738258T3
Authority
DK
Denmark
Prior art keywords
adam6 mice
adam6
mice
Prior art date
Application number
DK14154918.8T
Other languages
Danish (da)
Other versions
DK2738258T1 (en
DK2738258T4 (en
Inventor
Lynn Macdonald
Sean Stevens
Andrew J Murphy
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45998616&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2738258(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of DK2738258T1 publication Critical patent/DK2738258T1/en
Application granted granted Critical
Publication of DK2738258T3 publication Critical patent/DK2738258T3/en
Publication of DK2738258T4 publication Critical patent/DK2738258T4/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/22—Heating, cooling or ventilating [HVAC] devices the heat being derived otherwise than from the propulsion plant
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/3228—Cooling devices using compression characterised by refrigerant circuit configurations
    • B60H1/32281—Cooling devices using compression characterised by refrigerant circuit configurations comprising a single secondary circuit, e.g. at evaporator or condenser side
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/32—Cooling devices
    • B60H1/3204—Cooling devices using compression
    • B60H1/323—Cooling devices using compression characterised by comprising auxiliary or multiple systems, e.g. plurality of evaporators, or by involving auxiliary cooling devices
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00642—Control systems or circuits; Control members or indication devices for heating, cooling or ventilating devices
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/00192—Distribution of conditionned air to left and right part of passenger compartment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60H—ARRANGEMENTS OF HEATING, COOLING, VENTILATING OR OTHER AIR-TREATING DEVICES SPECIALLY ADAPTED FOR PASSENGER OR GOODS SPACES OF VEHICLES
    • B60H1/00—Heating, cooling or ventilating [HVAC] devices
    • B60H1/00007—Combined heating, ventilating, or cooling devices
    • B60H1/00021—Air flow details of HVAC devices
    • B60H2001/00185—Distribution of conditionned air
    • B60H2001/002—Distribution of conditionned air to front and rear part of passenger compartment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Thermal Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
DK14154918.8T 2011-02-25 2012-02-24 ADAM6 mice DK2738258T4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161446895P 2011-02-25 2011-02-25
US201161497650P 2011-06-16 2011-06-16
US201261595200P 2012-02-06 2012-02-06
EP12716101.6A EP2550363B1 (en) 2011-02-25 2012-02-24 Adam6 mice

Publications (3)

Publication Number Publication Date
DK2738258T1 DK2738258T1 (en) 2014-11-24
DK2738258T3 true DK2738258T3 (en) 2019-12-16
DK2738258T4 DK2738258T4 (en) 2023-05-08

Family

ID=45998616

Family Applications (6)

Application Number Title Priority Date Filing Date
DK14176593.3T DK2813573T1 (en) 2011-02-25 2012-02-24 ADAM6 mouse
DK14154918.8T DK2738258T4 (en) 2011-02-25 2012-02-24 ADAM6 mice
DK14154967.5T DK2738259T3 (en) 2011-02-25 2012-02-24 ADAM6 mice
DK22156414.9T DK4067496T5 (en) 2011-02-25 2012-02-24 ADAM6 mice
DK12192727.1T DK2578688T4 (en) 2011-02-25 2012-02-24 ADAM6 mice
DK12716101.6T DK2550363T3 (en) 2011-02-25 2012-02-24 ADAM6 mice

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK14176593.3T DK2813573T1 (en) 2011-02-25 2012-02-24 ADAM6 mouse

Family Applications After (4)

Application Number Title Priority Date Filing Date
DK14154967.5T DK2738259T3 (en) 2011-02-25 2012-02-24 ADAM6 mice
DK22156414.9T DK4067496T5 (en) 2011-02-25 2012-02-24 ADAM6 mice
DK12192727.1T DK2578688T4 (en) 2011-02-25 2012-02-24 ADAM6 mice
DK12716101.6T DK2550363T3 (en) 2011-02-25 2012-02-24 ADAM6 mice

Country Status (32)

Country Link
US (12) US8642835B2 (en)
EP (7) EP2738259B1 (en)
JP (7) JP2014507137A (en)
KR (1) KR101387377B1 (en)
CN (2) CN105861548B (en)
AU (5) AU2012243291B2 (en)
BR (1) BR112013021771B1 (en)
CA (1) CA2820824A1 (en)
CY (5) CY1116301T1 (en)
DE (5) DE14154967T1 (en)
DK (6) DK2813573T1 (en)
ES (6) ES2758974T5 (en)
FI (3) FI2578688T4 (en)
HK (2) HK1201292A1 (en)
HR (5) HRP20191895T4 (en)
HU (5) HUE062552T2 (en)
IL (4) IL226727A (en)
IN (1) IN2013CN07629A (en)
LT (4) LT2738258T (en)
ME (3) ME03732B (en)
MX (2) MX343009B (en)
MY (1) MY172713A (en)
NZ (3) NZ731926A (en)
PL (5) PL4067496T3 (en)
PT (5) PT2738258T (en)
RS (5) RS64280B1 (en)
RU (2) RU2582261C2 (en)
SG (4) SG10201405135RA (en)
SI (5) SI4067496T1 (en)
SM (5) SMT202000112T1 (en)
WO (1) WO2012141798A1 (en)
ZA (1) ZA201305998B (en)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
CA2492377C (en) 2002-07-18 2015-02-03 Crucell Holland B.V. Recombinant production of mixtures of antibodies
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
CA2527694C (en) 2003-05-30 2015-07-14 Hendricus Renerus Jacobus Mattheus Hoogenboom Fab library for the preparation of anti vegf and anti rabies virus fabs
RU2398882C2 (en) 2004-07-22 2010-09-10 Эрасмус Юниверсити Медикал Сентр Роттердам METHOD OF PRODUCING ANTIGEN-BINDING Vh DOMAIN, APPLICATION THEREOF
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
LT2505654T (en) 2010-02-08 2016-12-12 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
PT2601298T (en) 2010-08-02 2017-01-09 Regeneron Pharma Mice that make binding proteins comprising vl domains
RS64280B1 (en) 2011-02-25 2023-07-31 Regeneron Pharma Adam6 mice
WO2013006688A2 (en) 2011-07-05 2013-01-10 Duke University N-terminal deleted gp120 immunogens
RU2664232C2 (en) * 2011-08-05 2018-08-15 Регенерон Фармасьютикалз, Инк. Humanised universal light chain mice
CN103945689B (en) 2011-09-19 2016-10-19 科马布有限公司 The multifarious manipulation of immunoglobulin gene and multispecific antibody therapeutic agent
EP2758534B1 (en) 2011-09-19 2020-04-29 Kymab Limited Animals, repertoires & methods for the production of human antibodies
WO2013045916A1 (en) 2011-09-26 2013-04-04 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
EP2763699A4 (en) 2011-10-03 2015-05-20 Univ Duke VACCINE
KR20210113419A (en) 2011-10-17 2021-09-15 리제너론 파마슈티칼스 인코포레이티드 Restricted immunoglobulin heavy chain mice
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
GB201122047D0 (en) * 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
ES2720186T3 (en) 2011-12-20 2019-07-18 Regeneron Pharma Mice with humanized light chains
NZ793447A (en) * 2012-02-01 2024-05-31 Regeneron Pharma Humanized rodents that express heavy chains containing vl domains
SMT201900535T1 (en) 2012-03-16 2019-11-13 Regeneron Pharma Rodents expressing ph-sensitive immunoglobulin sequences
SI2825036T1 (en) 2012-03-16 2018-08-31 Regeneron Pharmaceuticals, Inc. Histidine engineered light chain antibodies and genetically modified rodents for generating the same
SG11201405164QA (en) 2012-03-16 2014-10-30 Regeneron Pharma Mice that produce antigen-binding proteins with ph-dependent binding characteristics
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
DK2838917T3 (en) 2012-04-20 2019-08-26 Merus Nv METHODS AND MEANS FOR CREATING HETERODIMER IG SIMILAR MOLECULES
NZ703689A (en) 2012-06-12 2016-05-27 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
AU2014214863B2 (en) 2013-02-06 2019-03-21 Duke University B cell lineage based immunogen design with humanized animals
KR101764800B1 (en) 2013-02-20 2017-08-04 리제너론 파마슈티칼스 인코포레이티드 Non-human animals with modified immunoglobulin heavy chain sequences
WO2014141189A1 (en) * 2013-03-14 2014-09-18 Erasmus University Medical Center Transgenic non-human mammal for antibody production
US10993420B2 (en) 2013-03-15 2021-05-04 Erasmus University Medical Center Production of heavy chain only antibodies in transgenic mammals
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
WO2015049517A2 (en) 2013-10-01 2015-04-09 Kymab Limited Animal models and therapeutic molecules
JP6267986B2 (en) * 2014-02-13 2018-01-24 株式会社特殊免疫研究所 In vivo evaluation method for molecular target substances that bind to specific human molecules
KR102276752B1 (en) * 2014-03-21 2021-07-13 리제너론 파마슈티칼스 인코포레이티드 Non-human animals that make single domain binding proteins
SG11201607015VA (en) 2014-03-21 2016-09-29 Regeneron Pharma V<sb>L</sb> ANTIGEN BINDING PROTEINS EXHIBITING DISTINCT BINDING CHARACTERISTICS
WO2016044745A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
CA2979702A1 (en) 2015-03-19 2016-09-22 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
SG11201805973WA (en) 2016-01-13 2018-08-30 Regeneron Pharma Rodents having an engineered heavy chain diversity region
CN109195443A (en) 2016-02-16 2019-01-11 雷杰纳荣制药公司 Non-human animal with saltant type kynurenin enzyme gene
JP7324583B2 (en) * 2016-05-20 2023-08-10 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods for breaking immune tolerance using multiple guide RNAs
DK3462853T3 (en) 2016-06-03 2023-04-03 Regeneron Pharma Rodents expressing exogenous terminal deoxynucleotidyl transferase
WO2017214089A1 (en) 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
IL266282B2 (en) 2016-11-04 2024-04-01 Regeneron Pharma Non-human animals with a transgenic immunoglobulin light chain locus
US11122042B1 (en) 2017-05-12 2021-09-14 F5 Networks, Inc. Methods for dynamically managing user access control and devices thereof
KR102760654B1 (en) 2017-06-07 2025-02-04 리제너론 파마슈티칼스 인코포레이티드 Compositions and methods for enzyme internalization
MX2020005830A (en) 2017-12-05 2020-08-20 Regeneron Pharma Non-human animals having an engineered immunoglobulin lambda light chain and uses thereof.
US20190292263A1 (en) 2018-03-24 2019-09-26 Regeneron Pharmaceuticals, Inc. Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
CA3093850A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
KR20210010916A (en) 2018-05-17 2021-01-28 리제너론 파마슈티칼스 인코포레이티드 Anti-CD63 antibodies, conjugates, and uses thereof
US12102070B2 (en) 2018-06-13 2024-10-01 Crystal Bioscience Inc. Camelization of a human variable domain by gene conversion
KR102617284B1 (en) 2018-06-14 2023-12-27 리제너론 파마슈티칼스 인코포레이티드 Non-human animals capable of dh-dh rearrangement in the immunoglobulin heavy chain coding sequences
CA3125380A1 (en) 2019-02-18 2020-08-27 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with humanized immunoglobulin locus
CN113473850A (en) 2019-02-22 2021-10-01 瑞泽恩制药公司 Rodents having genetically modified sodium channels and methods of use thereof
BR112021023683A2 (en) 2019-06-05 2022-02-01 Regeneron Pharma Genetically modified rodent and mouse, rodent embryo, genetically modified rodent or mouse b-cell, hybridoma, b-cell population, embryonic stem cell, mammalian cell, methods of producing an antibody, a heavy chain, a domain variable, from a collection of variable domains, from a light chain, from a nucleotide sequence, from a genetically modified rodent and from es cells, from generating a variable domain and in vitro to generate a recombinant rodent cell, and, vector of direction
DK3785536T3 (en) * 2019-08-28 2022-03-28 Trianni Inc Adam6 knockin mouse
US20220409732A1 (en) 2019-12-02 2022-12-29 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
CA3182925A1 (en) 2020-06-02 2021-12-09 Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Genetically modified non-human animals with common light chain immunoglobulin locus
JP2023540808A (en) 2020-09-11 2023-09-26 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Identification and production of antigen-specific antibodies
CN116848254A (en) 2020-12-16 2023-10-03 瑞泽恩制药公司 Mice expressing humanized Fc alpha receptors
TW202241934A (en) 2020-12-23 2022-11-01 美商再生元醫藥公司 Nucleic acids encoding anchor modified antibodies and uses thereof
KR20230124594A (en) 2020-12-23 2023-08-25 리제너론 파마슈티칼스 인코포레이티드 Method for obtaining antibodies that bind to transmembrane proteins and cells producing them
JP7579462B2 (en) 2021-04-20 2024-11-07 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Human antibodies to artemin and methods of use thereof
WO2024015816A1 (en) 2022-07-12 2024-01-18 Regeneron Pharmaceuticals, Inc. Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof
WO2024173248A1 (en) 2023-02-13 2024-08-22 Regeneron Pharmaceuticals, Inc. Treatment of muscle related disorders with anti-human cacng1 antibodies
WO2024229105A1 (en) 2023-05-02 2024-11-07 Regeneron Pharmaceuticals, Inc. Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells
WO2025014533A1 (en) 2023-07-10 2025-01-16 Regeneron Pharmaceuticals, Inc. Anti-human cacng1 antibody-drug conjugates and uses thereof

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1994012215A1 (en) * 1992-12-01 1994-06-09 Protein Design Labs, Inc. Humanized antibodies reactive with l-selectin
ES2384942T3 (en) * 1996-12-03 2012-07-16 Amgen Fremont Inc. Human antibodies that specifically bind TNF alpha
CN1203922A (en) * 1997-03-21 1999-01-06 三共株式会社 Humanized anti-human fas antibody
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
RU10506U1 (en) 1999-04-08 1999-08-16 Кривулин Виталий Николаевич MANUAL CULTIVATOR
WO2000073323A2 (en) * 1999-05-27 2000-12-07 Human Genome Sciences, Inc. Adam polynucleotides and polypeptides
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PE20020574A1 (en) 2000-12-06 2002-07-02 Wyeth Corp HUMANIZED ANTIBODIES THAT RECOGNIZE THE AMYLOID PEPTIDE BETA
US7034134B2 (en) 2001-04-26 2006-04-25 Bristol-Myers Squibb Company Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29
US7476536B2 (en) 2001-05-11 2009-01-13 Kirin Pharma Kabushiki Kaisha Artificial human chromosome containing human antibody a light chain gene
US7473557B2 (en) 2001-06-06 2009-01-06 Regeneron Pharmaceuticals, Inc. Method for targeting transcriptionally active loci
US20060199204A1 (en) 2001-10-05 2006-09-07 U.S. Epa Genetic testing for male factor infertility
WO2003031656A1 (en) 2001-10-05 2003-04-17 United States Environmental Protection Agency Genetic testing for male factor infertility
JP4099646B2 (en) 2002-06-04 2008-06-11 株式会社安川電機 Voice coil motor
CA2492377C (en) 2002-07-18 2015-02-03 Crucell Holland B.V. Recombinant production of mixtures of antibodies
RU2251699C1 (en) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Method for early and preclinical diagnostics of cervical cancer
CA2583750C (en) 2004-10-19 2015-11-24 Regeneron Pharmaceuticals, Inc. Methods for generating a rodent having a genetic modification
ATE416465T1 (en) 2005-06-30 2008-12-15 Borealis Tech Oy COVERING LAYER FOR POWER OR COMMUNICATION CABLES
WO2007117410A2 (en) * 2006-03-31 2007-10-18 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
DK2041177T3 (en) 2006-06-02 2012-02-27 Regeneron Pharma High affinity antibodies to human IL-6 receptor
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
US7659842B2 (en) 2007-10-24 2010-02-09 Infineon Technologies Ag Quantization error reduction in PWM full-MASH converters
WO2010039900A2 (en) 2008-09-30 2010-04-08 Aliva Biopharmaceuticals, Inc. Non-human mammals for the production of chimeric antibodies
KR101711222B1 (en) * 2008-12-18 2017-02-28 에라스무스 유니버시티 메디컬 센터 로테르담 Non-human transgenic animals expressing humanised antibodies and use therof
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
JP5399140B2 (en) * 2009-06-18 2014-01-29 株式会社タイトー Morse code communication system
EP2564695B1 (en) 2009-07-08 2015-04-15 Kymab Limited Animal models and therapeutic molecules
EP2509409B1 (en) * 2009-12-10 2016-07-27 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
US20120021409A1 (en) 2010-02-08 2012-01-26 Regeneron Pharmaceuticals, Inc. Common Light Chain Mouse
LT2505654T (en) 2010-02-08 2016-12-12 Regeneron Pharmaceuticals, Inc. Common light chain mouse
NZ605966A (en) * 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
RS64280B1 (en) 2011-02-25 2023-07-31 Regeneron Pharma Adam6 mice
RU2664232C2 (en) 2011-08-05 2018-08-15 Регенерон Фармасьютикалз, Инк. Humanised universal light chain mice
KR20210113419A (en) 2011-10-17 2021-09-15 리제너론 파마슈티칼스 인코포레이티드 Restricted immunoglobulin heavy chain mice
GB201118579D0 (en) 2011-10-27 2011-12-07 Micromass Ltd Control of ion populations
GB201122047D0 (en) 2011-12-21 2012-02-01 Kymab Ltd Transgenic animals
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
ES2720186T3 (en) 2011-12-20 2019-07-18 Regeneron Pharma Mice with humanized light chains
NZ703689A (en) 2012-06-12 2016-05-27 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci

Also Published As

Publication number Publication date
EP2813573A1 (en) 2014-12-17
SI4067496T1 (en) 2023-07-31
PL2738258T5 (en) 2023-05-15
SI2550363T1 (en) 2015-04-30
PT2550363E (en) 2015-03-16
RU2582261C2 (en) 2016-04-20
SMT202300173T1 (en) 2023-07-20
EP2578688B2 (en) 2023-02-08
RS64280B1 (en) 2023-07-31
US20140213773A1 (en) 2014-07-31
DK2550363T3 (en) 2015-03-23
US8642835B2 (en) 2014-02-04
HK1174490A1 (en) 2013-06-14
LT2578688T (en) 2019-11-11
PT2578688T (en) 2019-10-24
US11950578B2 (en) 2024-04-09
CN103429746B (en) 2016-05-11
LT2738259T (en) 2020-03-10
EP4067496A1 (en) 2022-10-05
HRP20191895T1 (en) 2020-01-10
HRP20192311T4 (en) 2023-05-12
US20120322108A1 (en) 2012-12-20
NZ731926A (en) 2021-07-30
SI2578688T1 (en) 2019-11-29
DE14154967T1 (en) 2014-08-28
SMT201500061B (en) 2015-05-05
ES2770424T3 (en) 2020-07-01
NZ718688A (en) 2017-07-28
MX2020009714A (en) 2020-10-07
PL2578688T5 (en) 2023-05-29
EP2738258B2 (en) 2023-02-01
US8697940B2 (en) 2014-04-15
AU2012243291A1 (en) 2013-05-09
ZA201305998B (en) 2016-07-27
EP2738259B1 (en) 2019-11-27
RS59413B2 (en) 2023-06-30
RS59661B2 (en) 2023-06-30
MX343009B (en) 2016-10-21
DK4067496T3 (en) 2023-06-26
CN103429746A (en) 2013-12-04
CA2820824A1 (en) 2012-10-18
HRP20150262T1 (en) 2015-04-10
AU2017251802A1 (en) 2017-11-16
DE14176593T1 (en) 2015-03-05
JP2019187446A (en) 2019-10-31
EP4067496B1 (en) 2023-03-29
US9944716B2 (en) 2018-04-17
PT4067496T (en) 2023-06-07
WO2012141798A1 (en) 2012-10-18
DK2738259T1 (en) 2014-11-24
ME03732B (en) 2021-01-20
ME02106B (en) 2015-10-20
ES2758974T5 (en) 2023-06-08
CN105861548A (en) 2016-08-17
CY1126091T1 (en) 2023-11-15
US20240306617A1 (en) 2024-09-19
SMT201900744T1 (en) 2020-01-14
JP2016135143A (en) 2016-07-28
EP2738258A3 (en) 2014-09-24
JP2018143250A (en) 2018-09-20
MX2013009649A (en) 2013-09-26
RS59413B1 (en) 2019-11-29
PL4067496T3 (en) 2023-07-31
DE12192727T1 (en) 2013-07-11
US20210105985A1 (en) 2021-04-15
JP2022071051A (en) 2022-05-13
EP2578688A1 (en) 2013-04-10
ES2805364T3 (en) 2021-02-11
US10072095B2 (en) 2018-09-11
DK2578688T1 (en) 2014-11-24
NZ797720A (en) 2024-09-27
US10905109B2 (en) 2021-02-02
HUE024534T2 (en) 2016-01-28
IL261243B (en) 2019-08-29
IL268671A (en) 2019-10-31
NZ703609A (en) 2016-04-29
RU2013125717A (en) 2014-12-10
ES2946169T3 (en) 2023-07-13
HUE062552T2 (en) 2023-11-28
HRP20191895T4 (en) 2023-05-12
DK2578688T3 (en) 2019-10-28
SI2738258T2 (en) 2023-05-31
IL226727A (en) 2016-08-31
US9932408B2 (en) 2018-04-03
PT2738258T (en) 2019-12-10
IN2013CN07629A (en) 2015-08-07
CN105861548B (en) 2020-01-10
CY1122205T1 (en) 2020-11-25
CY1122459T1 (en) 2021-01-27
EP2738258B1 (en) 2019-09-25
IL273986A (en) 2020-05-31
EP3744850A1 (en) 2020-12-02
ES2748832T5 (en) 2023-06-08
HK1201292A1 (en) 2015-08-28
SG10201913155QA (en) 2020-02-27
US20180346599A1 (en) 2018-12-06
PT2738259T (en) 2020-02-18
EP2738259A2 (en) 2014-06-04
US10905108B2 (en) 2021-02-02
RS53880B1 (en) 2015-08-31
LT4067496T (en) 2023-06-12
EP2738258A2 (en) 2014-06-04
BR112013021771A2 (en) 2017-07-04
EP2550363A1 (en) 2013-01-30
DE12716101T1 (en) 2013-05-08
ES2758974T3 (en) 2020-05-07
HUE046081T2 (en) 2020-01-28
KR101387377B1 (en) 2014-04-21
JP2014110814A (en) 2014-06-19
PL2738258T3 (en) 2020-08-24
PL2550363T3 (en) 2015-05-29
HRP20192311T1 (en) 2020-03-20
CY1122820T1 (en) 2021-05-05
DK2738258T1 (en) 2014-11-24
JP5866127B2 (en) 2016-02-17
SMT202000112T1 (en) 2020-05-08
DE14154918T1 (en) 2014-08-21
RU2016109443A (en) 2018-11-26
AU2020201279A1 (en) 2020-03-12
SI2738258T1 (en) 2020-01-31
ES2748832T3 (en) 2020-03-18
ME03537B (en) 2020-04-20
NZ612643A (en) 2015-06-26
HUE046746T2 (en) 2020-03-30
JP2015107131A (en) 2015-06-11
DK4067496T5 (en) 2024-07-22
EP2813573B1 (en) 2020-04-22
HUE047687T2 (en) 2020-05-28
EP2738259A3 (en) 2014-07-30
US20130254911A1 (en) 2013-09-26
AU2012243291B2 (en) 2015-07-09
DK2813573T1 (en) 2015-01-12
SI2738259T1 (en) 2020-06-30
KR20130116375A (en) 2013-10-23
PL2738259T3 (en) 2020-08-24
DK2738259T3 (en) 2020-02-17
US10577430B2 (en) 2020-03-03
US20180345760A1 (en) 2018-12-06
CY1116301T1 (en) 2017-02-08
US20150210776A1 (en) 2015-07-30
RS59661B1 (en) 2020-01-31
US20150201589A1 (en) 2015-07-23
HRP20230526T1 (en) 2023-09-01
RU2722373C2 (en) 2020-05-29
FI2578688T4 (en) 2023-05-05
MY172713A (en) 2019-12-11
DK2738258T4 (en) 2023-05-08
IL268671B (en) 2020-05-31
IL273986B (en) 2021-04-29
FI2738258T4 (en) 2023-05-05
US12207628B2 (en) 2025-01-28
JP2014507137A (en) 2014-03-27
US20210105984A1 (en) 2021-04-15
US10694725B2 (en) 2020-06-30
US20180346598A1 (en) 2018-12-06
RS59929B1 (en) 2020-03-31
DK2578688T4 (en) 2023-05-08
NZ776770A (en) 2023-03-31
BR112013021771B1 (en) 2022-11-16
US20180362663A1 (en) 2018-12-20
ES2532487T3 (en) 2015-03-27
AU2022206806A1 (en) 2022-08-18
EP2578688B1 (en) 2019-07-24
SG192933A1 (en) 2013-09-30
EP2550363B1 (en) 2014-12-10
PL2578688T3 (en) 2020-05-18
HRP20200294T1 (en) 2020-05-29
RU2016109443A3 (en) 2019-07-24
SI2578688T2 (en) 2023-05-31
AU2015238806A1 (en) 2015-10-29
LT2738258T (en) 2020-01-10
SG10201913160QA (en) 2020-03-30
IL261243A (en) 2018-10-31
FI4067496T3 (en) 2023-05-24
SMT201900581T1 (en) 2019-11-13
SG10201405135RA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
DK4067496T5 (en) ADAM6 mice
DK2744810T4 (en) TENOFOVIR-ALAFENAMIDE-HEMIFUMARATE
EP2780065A4 (en) NASALMASKENSYSTEM
BR112014002399A2 (en) set
EP2768410A4 (en) EXTENDERMANSCHETTENSYSTEM
EP2664141A4 (en) ENTBLOCKIERUNGSFILTERUNG
DK2769050T3 (en) Propsensor
EP2748335A4 (en) URINBIOMARKER
BR112014000879A2 (en) deflegmator
DK3272861T3 (en) ALPHA-galactosidase-FORMATIONS
DE102011100082A8 (en) Traygreifvorrichtung
CO6960543A2 (en) 2-thiopyrimidinones
EP2786752A4 (en) ROPINIUM-CONTAINING HEFTPFLASTER
EP2768739A4 (en) AUGENBADBEHÄLTER
DK3141251T3 (en) COLOSCOPY - PREPARATION
DE112011104936A5 (en) Stanzstauchniet
EP2760803A4 (en) GEOPOLYMERPRODUKT
EP2788163A4 (en) NACHGUSSSYSTEM
EP2698098A4 (en) campimeter
DE112012000958A5 (en) bucksaw
DK2476953T3 (en) FLUIDBEDKEDEL
EP2729467A4 (en) KRYPTATVERBINDUNGEN
DE112012002458A5 (en) hydrotransformer
EP2694655A4 (en) pavec
DE112012000819A5 (en) Gurtbandfänger